<DOC>
	<DOC>NCT00984789</DOC>
	<brief_summary>400 healthy women needed contraception will be asked to participate in this study. Half will be given EVRA, half will be given FC Patch low. They will be expected to apply the patches for 21 days of their cycle, for 7 cycles in total. The study will compare the patterns of menstrual bleeding on these two treatments, plus how effective they are at preventing pregnancy, general safety, and their acceptability to the participants.</brief_summary>
	<brief_title>Birth Control Patch Study</brief_title>
	<detailed_description />
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Femovan</mesh_term>
	<mesh_term>Gestodene</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>Healthy women requesting contraception aged 1835 years old Smokers must not be older than 30 at time of informed consent History of regular cyclic menstrual periods, normal cervical smear Pregnancy or lactation Obesity (BMI&gt;30), hypersensitivity to any ingredients of the study drug, significant skin reaction to transdermal preparations, any diseases/conditions that can compromise the functions of the body system (resulting in altered absorption/accumulation/ metabolism/excretion of the study drug), any diseases / conditions that may worsen under hormonal treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Transdermal Patch</keyword>
	<keyword>Bleeding</keyword>
	<keyword>Pregnancy</keyword>
</DOC>